ERBB2 and breast cancer: Margetuximab shares HER2 specificity with trastuzumab, binding to ECD4, but distinguishes itself in that the Fc portion of the antibody was engineered to enhance the ADCC of margetuximab-bound BC cells by the innate immune system relative to trastuzumab [52].